US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Metsera Inc.

20.89

+1.326.75%

Volume:1.22M

Turnover:26.21M

Market Cap:2.19B

PE:-1.44

High:22.57

Open:19.30

Low:18.64

Close:19.57

Loading ...

Overview Company News Filings

U.S. Small Caps Close Up; Metsera Top Leaders

BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio Progress

Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share

MT Newswires Live

Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M

MT Newswires Live

Metsera Inc: Completed IPO With Gross Proceeds of Approximately $316.2 Mln, Extending Runway Into 2027

THOMSON REUTERS

Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera, Inc. Approves 2024 Executive Cash Bonuses

Q4 2024 Amneal Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents

Metsera to Present at TD Cowen’s 45th Annual Health Care Conference

Wall Street bullish on Metsera following January IPO on obesity drug pipeline

Why this newly public biotech could become a force in obesity treatments

BofA Securities Initiates Metsera at Buy With $38 Price Target

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE- Eli Lilly, Krispy Kreme, PayPal

Metsera Initiated at Outperform by Evercore ISI Group

Evercore ISI Initiates Metsera at Outperform

MT Newswires Live

Metsera Initiated at Buy by B of A Securities

BUZZ-U.S. STOCKS ON THE MOVE- Zoom Communications, Home Depot, Civitas Resources

BUZZ-BofA starts coverage on weight-loss drug developer Metsera with 'buy' rating

Metsera initiated with an Outperform at Evercore ISI

Guggenheim Initiates Metsera at Buy With $56 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MTSR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTSR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTSR\",,,,,undefined,":{"symbol":"MTSR","market":"US","secType":"STK","nameCN":"Metsera Inc.","latestPrice":20.89,"timestamp":1745262369363,"preClose":19.57,"halted":0,"volume":1220559,"delay":0,"floatShares":59968852,"shares":105050219,"eps":-14.490661,"marketStatus":"Trading","change":1.32,"latestTime":"04-21 15:06:10 EDT","open":19.3,"high":22.57,"low":18.6401,"amount":26208014.946819,"amplitude":0.200812,"askPrice":21,"askSize":100,"bidPrice":20.72,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-14.490661,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":19.57,"preHourTrading":{"tag":"盘前","latestPrice":19.3,"preClose":19.57,"latestTime":"09:28 EDT","volume":2458,"amount":48090.912564,"timestamp":1745242083000},"postHourTrading":{"tag":"盘后","latestPrice":19.62,"preClose":19.57,"latestTime":"19:52 EDT","volume":4051,"amount":79275.9251,"timestamp":1744933941686},"volumeRatio":0.904153},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTSR\",,,,,undefined,":{"symbol":"MTSR","floatShares":59968852,"roa":"-27.09%","roe":"-108.40%","lyrEps":-14.490661,"volumeRatio":0.904153,"shares":105050219,"dividePrice":0,"high":22.57,"amplitude":0.200812,"preClose":19.57,"low":18.6401,"week52Low":12.3,"pbRate":"-8.66","week52High":32.8082,"institutionHeld":0,"latestPrice":20.89,"committee":0.5,"eps":-14.490661,"divideRate":0,"volume":1220559,"delay":0,"ttmEps":-14.490661,"open":19.3,"prevYearClose":18,"prevWeekClose":19.57,"prevMonthClose":27.22,"prevQuarterClose":27.22,"fiveDayClose":14,"twentyDayClose":28.02,"sixtyDayClose":18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTSR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527514952","title":"U.S. Small Caps Close Up; Metsera Top Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2527514952","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527514952?lang=en_us&edition=fundamental","pubTime":"2025-04-15 04:21","pubTimestamp":1744662060,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies increased Monday, as the Russell 2000 Index gained 1.1%, and the S&P Small Cap 600 Index was up 1.1%.Among companies with a market value of $1 billion to $6.7 billion, Metsera Inc. was the best performer during the session, surging 30%, followed by MP Materials Corp., which surged 22%. Certara Inc. shares jumped 12%, Diginex Ltd. surged 11%, and shares of Viridian Therapeutics Inc. jumped 11%.Exodus Movement Inc. was the biggest laggard, dropping 11%, followed by shares of Plug Power Inc., which dropped 7.1%. Shares of Kenon Holdings Ltd. dropped 5.7%, Peabody Energy Corp. shares plunged 5.5%, and Innodata Inc. tumbled 5.2%.Major U.S. stock indexes closed up Monday with the Nasdaq Composite Index adding 0.6%. Meanwhile, the S&P 500 Index gained 0.8%, and the Dow Jones Industrial Average added 0.8%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR"],"gpt_icon":0},{"id":"2522795538","title":"BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522795538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522795538?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:44","pubTimestamp":1742989499,"startTime":"0","endTime":"0","summary":"BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio ProgressMarch 26 (Reuters) - Metsera Inc MTSR.O:METSERA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA92XKL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","BK4139"],"gpt_icon":1},{"id":"2522187964","title":"Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187964","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187964?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:24","pubTimestamp":1742988265,"startTime":"0","endTime":"0","summary":"Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2522935879","title":"Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935879?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:23","pubTimestamp":1742988224,"startTime":"0","endTime":"0","summary":"Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSS","MTSR"],"gpt_icon":0},{"id":"2522820423","title":"Metsera Inc: Completed IPO With Gross Proceeds of Approximately $316.2 Mln, Extending Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2522820423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522820423?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986837,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA92XKL3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2522829878","title":"Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522829878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522829878?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025. Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1. Oral formulation optimization study on track to support initiation of clinical trials for MET-224 and MET097 , with MET-224 data expected in late 2025. Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027. NEW YORK, March 26, 2025  -- Metsera, Inc. , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial results and provided an update on pipeline progress.With the completion of our recent IPO, we have substantial capital to continue this momentum, enabled by our highly experienced team and committed partners. We expect 2025 to be anot","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","PRGS","RA","LU2065732104.USD","IPO","BK4097","BK4139"],"gpt_icon":0},{"id":"2518783956","title":"Metsera, Inc. Approves 2024 Executive Cash Bonuses","url":"https://stock-news.laohu8.com/highlight/detail?id=2518783956","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518783956?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:33","pubTimestamp":1741638825,"startTime":"0","endTime":"0","summary":"Metsera, Inc. ( ($MTSR) ) just unveiled an update. On March 7, 2025, Metsera, Inc. announced that its Board of Directors approved the 2024 annual c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metsera-inc-approves-2024-executive-cash-bonuses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metsera-inc-approves-2024-executive-cash-bonuses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MTSR"],"gpt_icon":0},{"id":"2516530651","title":"Q4 2024 Amneal Pharmaceuticals Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2516530651","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516530651?lang=en_us&edition=fundamental","pubTime":"2025-03-01 18:02","pubTimestamp":1740823351,"startTime":"0","endTime":"0","summary":"Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc.Anastasios Konidaris; Chief Financial Officer, Executive Vice President; Amneal Pharmaceuticals Inc.Joe Renda; Senior Vice President, Chief Commercial Officer-Specialty; Amneal Pharmaceuticals Inc.Jason Daly; Senior Vice President, Chief Legal Officer, Corporate Secretary; Amneal Pharmaceuticals Inc.Thank you, Tony. Good morning, everyone. At Amneal, we're much more than another generics company. We are an American biopharmaceutical company with a track record of excellence in delivering high-quality complex pharmaceuticals at speed and scale. We are a leader in an essential industry, providing millions of patients with access to affordable and innovative medicines. 2024 was an exceptional year where Amneal delivered stellar financial performance with double-digit revenue and adjusted EBITDA growth and reducing net leverage below 4 times. All segments grew revenues double digits. This ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-amneal-pharmaceuticals-inc-100231626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTSR"],"gpt_icon":0},{"id":"2514902839","title":"Metsera to Present at TD Cowen’s 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514902839","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514902839?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 26, 2025  -- Metsera, Inc.  , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metsera-present-td-cowen-45th-120000026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4207","BK4585","COWN","MTSR","BK4566","TD","BK4127","BK4139"],"gpt_icon":0},{"id":"2514043635","title":"Wall Street bullish on Metsera following January IPO on obesity drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2514043635","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514043635?lang=en_us&edition=fundamental","pubTime":"2025-02-26 03:04","pubTimestamp":1740510255,"startTime":"0","endTime":"0","summary":"Investing.com --Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a potential acquisition target for larger biopharma firms looking to enter the obesity market.Guggenheim rated Metsera a \"Buy\" with a $56 price target on its ultra-long-acting nutrient-stimulating hormone  analog pipeline. The firm sees Metsera’s lead GLP-1 receptor agonist, MET-097i, as a strong contender in the obesity market, with combination potential driving further value. Guggenheim noted that positive data in late 2025 could double the stock’s value over the next 18-24 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-bullish-metsera-following-190415270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MTSR"],"gpt_icon":0},{"id":"2514010770","title":"Why this newly public biotech could become a force in obesity treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2514010770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514010770?lang=en_us&edition=fundamental","pubTime":"2025-02-26 02:42","pubTimestamp":1740508920,"startTime":"0","endTime":"0","summary":"Metsera's GLP-1 peptide has a long half-life, meaning it could be administered once a month. And the company is ready to scale up.There's a new kid on the block when it comes to drug companies developing treatments for obesity, and this one has a clear advantage over rivals.Metsera Inc. , a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing treatments, as well as an oral peptide delivery technology, according to Evercore ISI analysts.That's not all. Metsera's GLP-1 peptide also has a long half-life, which could allow for monthly dosing, a more convenient administration system than the current approved drugs, which require weekly injections.\"Between the long half-life of GLP-1 peptide and slightly improved bioavailability in oral tech, Metsera's API math for oral is quite reasonable/doable,\" the analysts wrote.The company has launched a 28-week, double-blind, pla","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTSR","BK6520","OTX.SI","AMRX","BK4599","BK4585","BK6100","BK4007","BK4588","VKTX"],"gpt_icon":0},{"id":"2514006090","title":"BofA Securities Initiates Metsera at Buy With $38 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514006090","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514006090?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:49","pubTimestamp":1740494941,"startTime":"0","endTime":"0","summary":"Price: 30.26, Change: +0.45, Percent Change: +1.51","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2514097110","title":"BUZZ-U.S. STOCKS ON THE MOVE-  Eli Lilly, Krispy Kreme, PayPal","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097110","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514097110?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:30","pubTimestamp":1740493805,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE- Eli Lilly, Krispy Kreme, PayPalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL6N3PG0G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA","PYPL","YY","DNUT","NEM","MTSR","HD","NVDS.UK","NVIW.SI","SNVD.UK","CSCO","AS","CIVI","EVS.SI","CHGG","AU","ONVO","CAKE","IART","BBNX","ZM","02020","NIO.SI","NVD3.UK","KDP","3NVD.UK","CLF","DOMH","PLNT","SRE","LLY","BKSY","EVER","PTLO","NVD2.UK","HRMY"],"gpt_icon":1},{"id":"2514099996","title":"Metsera Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099996?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:05","pubTimestamp":1740488700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTSR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 08:05 ET (13:05 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR"],"gpt_icon":0},{"id":"2514962060","title":"Evercore ISI Initiates Metsera at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2514962060","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514962060?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488448,"startTime":"0","endTime":"0","summary":"Evercore ISI Initiates Metsera at Outperform","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2514096755","title":"Metsera Initiated at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096755","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096755?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:50","pubTimestamp":1740487800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTSR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 07:50 ET (12:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTSR"],"gpt_icon":0},{"id":"2514355093","title":"BUZZ-U.S. STOCKS ON THE MOVE- Zoom Communications, Home Depot, Civitas Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355093","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355093?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:10","pubTimestamp":1740485423,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Zoom Communications, Home Depot, Civitas ResourcesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL6N3PG0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDX","02015","ANPDY","02020","DOMH","COIN","LI","LU1548497426.USD","NVDA","NVDS","U","89888","09866","NVDY","NVD","LU0957808578.USD","NVD3.UK","EVS.SI","SNVD.UK","09888","LU2092627202.USD","NVDD","HIMS","RIOT","MARA","XPEV","CIVI","ZM","NVDU","YY","2NVD.UK","LU0043850808.USD","09868","BIDU","EVER","3NVD.UK","NIO.SI","BK4587","82020","LU1069344957.HKD","NVDS.UK","NVIW.SI","NIO","LU0056508442.USD","NVD2.UK","MTSR","IE0004091025.USD","HD","AS","NVDL"],"gpt_icon":1},{"id":"2514060775","title":"BUZZ-BofA starts coverage on weight-loss drug developer Metsera with 'buy' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514060775","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514060775?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:49","pubTimestamp":1740484167,"startTime":"0","endTime":"0","summary":"BUZZ-BofA starts coverage on weight-loss drug developer Metsera with 'buy' rating** BofA Global Research starts coverage on weight-loss drug developer Metsera MTSR.O with \"buy\" rating and $38 PT** PT represents a 27.5% upside to stock's last close** MTSR is poised to \"break into the obesity market\", which is projected to reach ~$170 bln by 2030, with a unique combination of both \"oral and injectable platforms\", setting it apart from its peers - brokerage** Company's lead obesity assets, MET-097i and MET-233i, have \"comparatively long half-lives\" and offer a convenient dosing schedule, with no dose changes needed at first, and just monthly injections afterwards, BofA says** MTSR's oral peptide, MET-224o, could have \"bioavailability that is 5-6x higher\" than the currently approved oral peptide, Novo Nordisk's NOVOb.CO Rybelsus - brokerage** Estimates risk-adjusted revenue of $2.1 bln and $2.5 bln by 2040 for MTSR's lead assets MET-097 and MET-097+MET-233, respectively  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAC","MTSR"],"gpt_icon":0},{"id":"2514060974","title":"Metsera initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2514060974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514060974?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:40","pubTimestamp":1740483610,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 programs in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metsera-initiated-with-an-outperform-at-evercore-isi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metsera-initiated-with-an-outperform-at-evercore-isi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTSR"],"gpt_icon":0},{"id":"2514677150","title":"Guggenheim Initiates Metsera at Buy With $56 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514677150","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514677150?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:32","pubTimestamp":1740483151,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Metsera at Buy With $56 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTSR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-26","symbol":"MTSR","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742961600000,"reportTimeType":"pre","actualEps":-3.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTSR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTSR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTSR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTSR","date":"2025-04-17","current":-8.815846,"percent":0.857143,"low":-55.8522,"twenty":-18.585291,"median":-16.597864,"eighty":-11.231036,"high":-6.570442,"avg":-15.990528,"sd":6.909743,"marketCap":1843631343},"quantilePoints":[{"date":"2025-02-07","current":-17.973411,"twenty":-17.939327,"median":-17.8882,"eighty":-17.837073,"marketCap":3042628924},{"date":"2025-02-14","current":-18.277736,"twenty":-18.639274,"median":-18.277736,"eighty":-17.958804,"marketCap":3094146515},{"date":"2025-02-21","current":-19.257661,"twenty":-19.263748,"median":-18.612493,"eighty":-17.973411,"marketCap":3260033158},{"date":"2025-02-28","current":-15.222317,"twenty":-19.263748,"median":-18.292952,"eighty":-17.802989,"marketCap":2576909901},{"date":"2025-03-07","current":-16.749262,"twenty":-19.257661,"median":-17.973411,"eighty":-16.634383,"marketCap":2835398748},{"date":"2025-03-14","current":-15.094245,"twenty":-18.72205,"median":-17.767653,"eighty":-15.847091,"marketCap":2555229332},{"date":"2025-03-21","current":-17.309229,"twenty":-18.72205,"median":-17.732316,"eighty":-15.847091,"marketCap":2930192911},{"date":"2025-03-28","current":-15.074845,"twenty":-18.72205,"median":-17.767653,"eighty":-15.847091,"marketCap":3152557072},{"date":"2025-04-04","current":-10.624224,"twenty":-18.709149,"median":-17.433667,"eighty":-15.417782,"marketCap":2221812131},{"date":"2025-04-11","current":-6.570442,"twenty":-18.612493,"median":-16.926585,"eighty":-14.065167,"marketCap":1374056864},{"date":"2025-04-17","current":-8.815846,"twenty":-18.585291,"median":-16.597864,"eighty":-11.231036,"marketCap":1843631343}],"updateTime":1745230973551}}}